In 2019, the results of health insurance negotiation will be published! Four major PD-1 only enter the bureau!

Today (November 28), the State Medical Security Bureau and the Ministry of human resources and Social Security announced the full version of the 2019 national directory of drugs for basic medical insurance, work injury insurance and maternity insurance, which contains 2709 drugs Compared with 2017 edition, 218 drugs were transferred in, 154 drugs were transferred out, a net increase of 64 The new catalogue will be put into effect on January 1 From the final list, all five essential drugs were negotiated successfully, 22 anticancer drugs, 7 drugs for rare diseases, 14 drugs for chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.) and 4 drugs for children were negotiated successfully At the same time, most of the drugs successfully negotiated in this negotiation are new drugs launched in recent years, many of which are newly launched in 2018, and a total of 8 of 12 domestic major innovative drugs have been negotiated However, in the four types of PD-1 that have been widely spread before, only Cinda silimab has successfully entered the medical insurance, which just shows that the national health insurance bureau is more cautious about including the high price of PD-1 In this negotiation, the price of 70 new drugs decreased by 60.7% on average, and that of 27 renewed drugs decreased by 26.4% on average The patients' personal burden is reduced by more than 80% and the individual drug burden is reduced by more than 95% Among them, the average decrease rate of three kinds of hepatitis C treatment drugs is more than 85%, and the average decrease rate of cancer, diabetes and other treatment drugs is about 65%, which makes the "noble medicine" offer "civilian price" The drug adjustment is mainly through the negotiation of drug enterprises, which is the largest negotiation since the establishment of the medical insurance system in China In recent years, most of the drugs that have been successfully negotiated are new drugs with high clinical value, involving more than 10 clinical treatment fields such as cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc Through the latest negotiation, in the new version of the national medical insurance drug catalog, another 70 drugs are added to the ranks of medical insurance reimbursement, and another 27 drugs are "renewed" All of these 97 drugs will be included in the scope of class B drugs in the medical insurance catalog These drugs are: penicillin this article is the content reprinted by yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.